Bonus Biogroup
Clinical-stage biotechnology company developing therapies for tissue regeneration, live human bone graft, cell therapy drug for inflammation & tissue dam age.
Stock chart
Analyses on Bonus Biogroup (3)
- March 31, 2026March 31, 2026
- Follow-up
Bonus Biogroup: The Investigation Overhang And The Option-Loan Structure As A Hidden Cost Of Capital
Bonus Biogroup is not dealing only with a need for capital but also with a credibility discount: an investigation file that has moved to prosecutors, an option-loan structure that still remained open at the end of 2025, and compensation agreements that tie share appreciation and…
- Follow-up
Bonus Biogroup: How Much Dilution Is Still Needed To Reach Phase III
Bonus Biogroup has already built a 2026 equity bridge, but it still has not closed the math required to reach Phase III. Even in a favorable U.S. offering scenario, the company still appears dependent on prioritization, a partner, or more equity.
Bonus Biogroup 2025: The Clinical Story Is Advancing, but the Funding Gap Is Still Open
Bonus Biogroup has already shown that it has two advanced clinical assets and approved manufacturing infrastructure, but the bottleneck has shifted from science to funding, regulation, and commercialization.
